Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 16/20 | 0.52 |
| ▸ | DPP8 | Q6V1X1 | 5/20 | 0.52 |
| ▸ | DPP9 | Q86TI2 | 5/20 | 0.52 |
| ▸ | FAP | Q12884 | 3/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL464954 | 1.00 | DPP4 (0.52) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL464955 | 1.00 | DPP4 (0.52) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL7178931 | 0.89 | DPP4 (0.41) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL7178928 | 0.89 | DPP4 (0.41) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL7178937 | 0.86 | DPP4 (0.39) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL7257702 | 0.85 | DPP4 (0.48) | DPP4DPP8DPP9FAP | |
| SCHEMBL6172387 | 0.85 | DPP4 (0.48) | DPP4DPP8DPP9FAP | |
| SCHEMBL6172382 | 0.85 | DPP4 (0.48) | DPP4DPP8DPP9FAP | |
| SCHEMBL7177403 | 0.84 | DPP4 (0.51) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL6489621 | 0.84 | DPP4 (0.51) | DPP4DPP8DPP9FAPDPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8980322-B2 | Controlled release composition | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-03-17 | — | — | US | disclosed |
| US-20060177509-A1 | Controlled release composition | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-08-10 | — | — | US | disclosed |
| US-20060039974-A1 | Sustained release preparation | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-02-23 | — | — | US | disclosed |
| EP-1607088-A1 | CONTROLLED RELEASE COMPOSITION | Takeda Pharmaceutical Company Limited (JP) | 2005-12-21 | — | — | EP | disclosed |
| EP-1537880-A1 | SUSTAINED RELEASE PREPARATION | Takeda Pharmaceutical Company Limited (JP) | 2005-06-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060039974-A1 | Sustained release preparation | DPP4, DPP7, DPP3 | DPP4 1/4885DPP8 5/4885DPP9 4/4885 |
| US-20060177509-A1 | Controlled release composition | ATP6AP1, NSF, ATP6V1G1 | DPP4 2445/4885DPP8 2848/4885DPP9 1361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.